Good afternoon and welcome to Markets Desk.
Takeda Pharmaceutical cleared a meaningful regulatory hurdle today as the FDA approved Mimrylo, its new treatment for polycythemia vera, a rare blood disorder that drives overproduction of red blood cells. The approval adds a commercial catalyst to Takeda's pipeline and gives the company a foothold in an underserved rare disease market where treatment options have historically been limited.
Shifting to the artificial intelligence space, OpenAI is severing its contract with Cursor, the coding assistant startup acquired by SpaceX, citing trust concerns rooted in past conduct by Twitter under Elon Musk's ownership. OpenAI says it will not extend access to future models, a significant blow given how central frontier model access is to any AI product's competitive viability. The move signals that OpenAI is willing to use contract terms as a strategic lever against Musk-affiliated entities.
And on the macro policy front, Federal Reserve Governor Kevin Warsh used his Jackson Hole appearance to offer a cleaner read on how he interprets current economic conditions, though markets are still working to decode his precise reaction function. Investors want to know at what point Warsh would support rate cuts, and his remarks, while clarifying in tone, stopped short of delivering that answer definitively.
That's the tape. Markets Desk, signing off the floor.
